Strange day in Cannabis. Most of my holdings were down but the heavily shorted big names with US listings were up. Canopy, CRON and TLRY all up a decent amount.
Unlock season on MSOs might limit them.
Cresco's was today, coupled with brutal news.
GTII Thursday. Not too many shares, but shorts have been feasting on that in the lead-up to the unlock.
Curaleaf Dec. 31st.
Fun times ahead.
But Illinois is legalizing in January and that's no small thing - over 35% of the population of Canada. Legitimately huge for GTI and Cresco (although there's always a risk in GTI doing what Cresco did today at some point). So doing some napkin math... their growth this quarter might slow a BIT, just because they are working from a larger revenue base now and includes a lot of Essence revenue in a mature Nevada which will definitely slow the overall growth rate. But at the same time, most of their growth in general does come from increases in same-store-sales. Almost all of their primary underlying markets (IL, PA, Mass, Connecticut, Maryland, Ohio) are growing 15-25% per quarter and GTIs retail/wholesale sales will reflect that growth. I think they do a conservative $80m next quarter - puts them at
$220 million for fiscal year 2019 after
$62.5 million in 2018.
And that little thing called Illinois legalization should give them a decent boost the quarter after that to start 2020. Even assuming a modest 20% qoq growth for 2020 has them smashing
$500 million US in revenues for 2020 (a very conservative estimate) and I can't foresee a circumstance where they aren't profitable by year end. Current market cap is 1.7 billion. As long as the growth keeps coming consistently (I'd like to see 20%+ per quarter.. I understand they won't be able to do 40-50% since acquisitions may slow a bit during a time where cash is king, but organic growth is a good kind of growth and from what we've seen, entirely realistic) and they have the cashflow to continue operations (decent cash position right now and should be inching towards profitability in the coming quarters, which helps a shit ton), I don't mind holding a core long on them.
But I'm running out of US names to trust. I thought Cresco was for real. Was waiting for the unlock stuff to fade to buy them, but now I'm not so sure. They should do well next year but starting to see some red flags and I don't do red flags. Curaleaf has some sketchy dealings but they're just so big and I don't mind having a piece of them... Trulieve and GTI are the only two left that I have not seen any red flags out of and are pretty much a well-oiled machine (other than TRULs husbands criminal stuff). Cresco and HARV had potential but unfortunately both ran out of cash at a time where running low on cash is downright deadly. And Cresco just acquired the cash burning king, OH in a market that has insane potential but it will be rocky in the short-term.
2018/2019 was a race to build out as much as possible. 2020 will stress the importance of preserving cash, while sustaining strong organic growth and inching towards profitability. At least until SAFE passes...
Anyway the risk for GTI is dilution and/or predatory raises. It's a real risk, despite their strong cash position. But otherwise, until I see red flags pop up, I'm in for the ride. As far as cannabis companies go, outside of TRUL, they're about as well-oiled of a machine as it gets. Consistently executing on every level while maintaining strong, but controlled/strategic growth.